compounding semaglutide lawsuit news The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the Compounded' weight-loss drugs are a

Reporting Side Effects Through the MHRA Yellow Card Scheme Suspected side effects from retatrutide used outside a clinical trial should be reported via the MHRA Yellow Card Scheme

More extensive clinical trials are needed to shed more light on the effectiveness of retatrutide for T2D, and whether it may be limited due to the activation of the GCG receptors, which may exert anti-insulin effects

The protein sample was mixed with lipid (monoolein/cholesterol 10:1 by mass) at weight ratio of 2:3 using a syringe mixer

FDA approval of oral semaglutide for weight management in early 2026 introduced a new dosing variable: oral formulations require an empty stomach and specific water intake at a fixed daily time